Davide Arillotta

713 total citations · 2 hit papers
26 papers, 433 citations indexed

About

Davide Arillotta is a scholar working on Clinical Psychology, Toxicology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Davide Arillotta has authored 26 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Clinical Psychology, 13 papers in Toxicology and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Davide Arillotta's work include Psychedelics and Drug Studies (11 papers), Forensic Toxicology and Drug Analysis (11 papers) and Neurotransmitter Receptor Influence on Behavior (6 papers). Davide Arillotta is often cited by papers focused on Psychedelics and Drug Studies (11 papers), Forensic Toxicology and Drug Analysis (11 papers) and Neurotransmitter Receptor Influence on Behavior (6 papers). Davide Arillotta collaborates with scholars based in Italy, United Kingdom and Germany. Davide Arillotta's co-authors include Fabrizio Schifano, Amira Guirguis, John Corkery, Alessandro Vento, Flavia Napoletano, Valeria Catalani, Caroline Zangani, Giovanni Martinotti, Giuseppe Floresta and Eugenio Aguglia and has published in prestigious journals such as SHILAP Revista de lepidopterología, Experimental Neurology and Drugs.

In The Last Decade

Davide Arillotta

25 papers receiving 425 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach

2023 50 citations Davide Arillotta, Giuseppe Floresta et al. Brain Sciences profile →
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis

2024 35 citations Amira Guirguis, Stefania Chiappini et al. European Neuropsychopharmacology profile →

Peers

Davide Arillotta

TOXIC

EDM

PHARM

Markus Banger Germany

Alessandro Vento Italy

Chrystalla Kyriakou Italy

Marc Graf Switzerland

Lisa Blecha France

Antonella Bacosi Italy

Valeria Catalani Italy

Peter H. Schmidt Germany

Mario Páramo Spain

Caroline A. MacCallum Canada

Markus Banger Germany

Davide Arillotta

69 ×0.5

83 ×0.7

TOXIC

116 ×1.3

EDM

89 ×1.0

PHARM

72 ×0.9

Citations per year, relative to Davide Arillotta Davide Arillotta (= 1×) peers Markus Banger

Countries citing papers authored by Davide Arillotta

Since Specialization

Citations

This map shows the geographic impact of Davide Arillotta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davide Arillotta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davide Arillotta more than expected).

Fields of papers citing papers by Davide Arillotta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Davide Arillotta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davide Arillotta. The network helps show where Davide Arillotta may publish in the future.

Co-authorship network of co-authors of Davide Arillotta

This figure shows the co-authorship network connecting the top 25 collaborators of Davide Arillotta. A scholar is included among the top collaborators of Davide Arillotta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Davide Arillotta. Davide Arillotta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Floresta, Giuseppe, Alberto Granzotto, Vincenzo Patamia, et al.. (2025). Xylazine as an emerging new psychoactive substance; focuses on both 5‐HT₇ and κ‐opioid receptors' molecular interactions and isosteric replacement. Archiv der Pharmazie. 358(3). e2500041–e2500041. 1 indexed citations

Chiappini, Stefania, Alessio Mosca, Denis Pelletier, et al.. (2025). Adverse Drug Reactions Associated with Concomitant Use of Calcium Channel Blockers and Cocaine: An Analysis of FDA Adverse Events Reporting System Data. Journal of Clinical Medicine. 14(10). 3461–3461.

Schifano, Fabrizio, Stefania Bonaccorso, Davide Arillotta, et al.. (2025). Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues. Brain Sciences. 15(5). 424–424. 2 indexed citations

Maida, Nunzia La, Fabio Vaiano, C. Locatelli, et al.. (2025). The rising trend of MDPHP consumption: an Italian snapshot. Journal of Analytical Toxicology. 49(6). 417–421. 2 indexed citations

Guirguis, Amira, Stefania Chiappini, Rachel Vickers‐Smith, et al.. (2024). Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. European Neuropsychopharmacology. 82. 82–91. 35 indexed citations breakdown →

Floresta, Giuseppe, Davide Arillotta, Valeria Catalani, et al.. (2024). Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions. Scientia Pharmaceutica. 92(2). 17–17. 1 indexed citations

Scott, M.L., Giuseppe Floresta, Davide Arillotta, et al.. (2024). Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. SHILAP Revista de lepidopterología. 12(1). 13–13. 7 indexed citations

Arillotta, Davide, Giuseppe Floresta, Guy Pelletier, et al.. (2024). Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sciences. 14(6). 617–617. 24 indexed citations

Chiappini, Stefania, Amira Guirguis, Nicolò Schifano, et al.. (2024). Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 136. 111213–111213. 6 indexed citations

10.

Arillotta, Davide, Giuseppe Floresta, Amira Guirguis, et al.. (2023). GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sciences. 13(11). 1503–1503. 50 indexed citations breakdown →

11.

Schifano, Fabrizio, Valeria Catalani, Flavia Napoletano, et al.. (2022). Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals. Drugs. 82(6). 633–647. 26 indexed citations

12.

Munafò, Antonio, Davide Arillotta, Guido Mannaioni, et al.. (2022). Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?. Pharmaceuticals. 16(1). 68–68. 11 indexed citations

13.

Arillotta, Davide, Amira Guirguis, John Corkery, Norbert Scherbaum, & Fabrizio Schifano. (2021). COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. Brain Sciences. 11(7). 907–907. 12 indexed citations

14.

Catalani, Valeria, Davide Arillotta, John Corkery, et al.. (2021). Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. Frontiers in Psychiatry. 11. 632405–632405. 26 indexed citations

15.

Catalani, Valeria, John Corkery, Amira Guirguis, et al.. (2021). Psychonauts’ psychedelics: A systematic, multilingual, web-crawling exercise. European Neuropsychopharmacology. 49. 69–92. 10 indexed citations

16.

Schifano, Fabrizio, Stefania Chiappini, Andrea Miuli, et al.. (2021). New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. Experimental Neurology. 339. 113638–113638. 30 indexed citations

17.

Arillotta, Davide, Fabrizio Schifano, Flavia Napoletano, et al.. (2020). Novel Opioids: Systematic Web Crawling Within the e-Psychonauts’ Scenario. Frontiers in Neuroscience. 14. 149–149. 27 indexed citations

18.

Napoletano, Flavia, Fabrizio Schifano, John Corkery, et al.. (2020). The Psychonauts’ World of Cognitive Enhancers. Frontiers in Psychiatry. 11. 546796–546796. 21 indexed citations

19.

Schifano, Fabrizio, Flavia Napoletano, Davide Arillotta, et al.. (2019). The clinical challenges of synthetic cathinones. British Journal of Clinical Pharmacology. 86(3). 410–419. 49 indexed citations

20.

Fusar‐Poli, Laura, Natascia Brondino, Matteo Rocchetti, et al.. (2019). Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: A cross-sectional study. Psychiatry Research. 276. 203–209. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact